1. Availability of point-of-care HBV tests in resource-limited settings.
- Author
-
Lau DTY, Jackson K, Picchio CA, Kramvis A, Sonderup M, Lemoine M, Matthews G, Howell J, Coffin CS, Hellard M, Lee AU, Anderson DA, Kerth HA, Lee EE, Tavis JE, Dandri M, Revill PA, Spearman CW, Penicaud C, Levrero M, and El-Sayed M
- Abstract
Competing Interests: DTYL reports support from ICE HBV for travel to present this work at COLDA 2023. AK reports grants from CANSA Cancer Association of South Africa, consulting fees from Roche Diagnostics, and support for attending meetings from Virology Education, University of Witwatersrand, and WHO. MLem reports consulting fees from Abbott and honoraria from Cepheid for lectures and presentations. GM reports grants from ViiV and Jannsen. CSC reports grants from GSK, Gilead Sciences, Janssen, and Roche Pharmaceuticals, and has participated in a data safety monitoring board for GSK. MH reports grants from Gilead Sciences and AbbVie. DAA reports being an inventor on Burnet Institute patents for alanine aminotransferase point of care tests for liver disease (PCT/IB2017/055943) and for dimeric IgA point of care tests for liver cirrhosis (PCT/AU2021/050037), and stock in Nanjing DeShi Diagnostic Technology Co. Ltd, which has licensed the alanine aminotransferase point-of-care test patents from Burnet Institute for manufacture and sale in China. PAR reports grants from NHMRC and a patent pending for CRISPR Cas13b guides targeting HBV (2023901165). CWS reports support by Gilead Sciences to attend AASLD. MLev reports honoraria from AbbVie and Gilead for lectures and presentations and support for attending meetings from AbbVie, Madrigal, and Gilead. ME-S reports support by Gilead Sciences. All other authors declared no competing interests.
- Published
- 2024
- Full Text
- View/download PDF